Jundishapur Journal of Microbiology

Published by: Kowsar

Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity

Faezeh Najafzadeh 1 , Reza Shapouri 2 , Mehdi Rahnema 3 , Shadi Rokhsartalab Azar 4 and Anvarsadat Kianmehr 5 , *
Authors Information
1 Young Researchers Club, Bonab Branch, Islamic Azad University, Bonab, IR Iran
2 Department of Microbiology, Zanjan Branch, Islamic Azad University, Zanjan, IR Iran
3 Biologic Research Center, Zanjan Branch, Islamic Azad University, Zanjan, IR Iran
4 Young Researchers and Elite Club, Urmia Branch, Islamic Azad University, Urmia, IR Iran
5 Department of Medical Biotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: June 01, 2015, 8 (6); e17712
  • Published Online: June 27, 2015
  • Article Type: Research Article
  • Received: January 18, 2014
  • Revised: May 26, 2014
  • Accepted: June 7, 2014
  • DOI: 10.5812/jjm.8(5)2015.17712

To Cite: Najafzadeh F, Shapouri R, Rahnema M, Rokhsartalab Azar S, Kianmehr A. Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity, Jundishapur J Microbiol. 2015 ; 8(6):e17712. doi: 10.5812/jjm.8(5)2015.17712.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Siegel RE. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care. 2008; 53(4): 471-9
  • 2. Taheri ZM, Shahbazi N, Khoddami M. Genetic Diversity of pseudomonas aeruginosa Strains isolated from Hospitalized patients. Tanaffos. 2008; 7(1): 32-9
  • 3. Al-Zeer M, Masoud H. LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein. World J Microbiol Biotechnol . 2007; 23(11): 1541-9
  • 4. Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ, et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa Infections. J Infect Dis. 1996; 174(3): 537-43
  • 5. Cryz SJJ, Lang AB, Sadoff JC, Germanier R, Furer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun. 1987; 55(7): 1547-51[PubMed]
  • 6. Cryz SJ, Sadoff JC, Fiirer E, Germanier R. Pseudomonas aeruginosa Polysaccharide-Tetanus Toxoid Conjugate Vaccine: Safety and Immunogenicity in Humans. J Infect Dis. 1986; 154(4): 682-8
  • 7. Robinson A, Hudson MJ, Cranage MP. Vaccine Protocols. 2000;
  • 8. Midwinter A, Faine S, Adler B. Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived immuno-conjugates from Leptospira interrogans. J Med Microbiol. 1990; 33(3): 199-204
  • 9. Aspe M, Jensen L, Melegrito J, Sun M. The role of alginate and extracellular DNA in biofilm-meditated Pseudomonas aeruginosa gentamicin resistance. J Exp Microbiol Immunol. 2012; 16: 42-8
  • 10. Kashef N. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J Med Microbiol. 2006; 55(10): 1441-6
  • 11. Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun. 1994; 62(11): 5048-54[PubMed]
  • 12. Cryz SJ, Furer E, Cross AS, Wegmann A, Germanier R, Sadoff JC. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest. 1987; 80(1): 51-6[DOI][PubMed]
  • 13. Zeng X, Liu X, Bian J, Pei G, Dai H, Polyak SW, et al. Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011; 55(6): 3015-7[DOI][PubMed]
  • 14. Kunert A, Losse J, Gruszin C, Huhn M, Kaendler K, Mikkat S, et al. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol. 2007; 179(5): 2979-88[PubMed]
  • 15. Cryz SJ, Furer E, Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun. 1984; 43(3): 795-9[PubMed]
  • 16. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine. 2004; 22(7): 840-7[DOI][PubMed]
  • 17. Collier L, Balows A, Sussman M. Topley & Wilson's microbiology and microbial infections. 1998;
  • 18. Cryz SJ, Sadoff JC, Fürer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog. 1989; 6(1): 75-80
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments